Key result
Aspirin, cilostazol, and ramatroban demonstrated similar inhibitory effects on ADP-induced platelet aggregation, though aspirin more strongly inhibited thromboxane A2 formation.
Why the study?
How do the anti-platelet aggregatory effects of aspirin, cilostazol, and ramatroban compare in human platelet-rich plasma and whole blood?
Population
Human platelet-rich plasma (PRP) and whole blood (WB)
Comparison
Aspirin, cilostazol, and ramatroban vs Comparative effects between the three drugs
Design
Preclinical
Authors
Loading...
Animal findings require human validation before any clinical consideration; leaves open comparative efficacy in patients.
How do the anti-platelet aggregatory effects of aspirin, cilostazol, and ramatroban compare in human platelet-rich plasma and whole blood?
Aspirin, cilostazol, and ramatroban demonstrate distinct concentration-dependent and mechanistic profiles in inhibiting platelet aggregation and intraplatelet molecule release in vitro.
Kariyazono et al. (2004) studied this question. Aspirin, cilostazol, and ramatroban vs. Each other was evaluated on Platelet-rich plasma (PRP) and whole blood (WB) aggregation induced by agonists. Aspirin, cilostazol, and ramatroban demonstrated similar inhibitory effects on ADP-induced platelet aggregation, though aspirin more strongly inhibited thromboxane A2 formation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: